• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Wataru Ichikawa, Koichiro Uehara, +17 authors Yasuhiko Sakata
  • Medicine
  • British Journal of Cancer
  • 2015 (First Published: 1 May 2015)
  • Background:In Asians, the risk of irinotecan-induced severe toxicities is related in part to UGT1A1*6 (UGT, UDP glucuronosyltransferase) and UGT1A1*28, variant alleles that reduce the elimination ofContinue Reading
  • Hiroji Uemura, Satoshi Nagamori, +17 authors Nobuaki Matsubara
  • Medicine
  • Clinical advances in hematology & oncology : H&O
  • 2016 (First Published: 10 January 2016)
  • 167 Background: The ALSYMPCA study was conducted to evaluate the alpha-emitting radiopharmaceutical Radium-223 Chloride (BAY 88-8223) in patients with symptomatic bone metastases in CastrationContinue Reading
  • Hideaki Miyake, Yuto Matsushita, +5 authors Atsushi Otsuka
  • Medicine
  • International Journal of Clinical Oncology
  • 2019 (First Published: 1 July 2019)
  • BackgroundTo compare the prognostic outcomes between first-generation antiandrogen (FGA) and novel androgen-receptor-axis-targeted agent (ARATA) as first-line therapy in patients with non-metastaticContinue Reading
  • Atsushi Otsuka, Takahisa Suzuki, +6 authors Hideaki Miyake
  • Medicine
  • Lower urinary tract symptoms
  • 2019 (First Published: 1 April 2019)
  • OBJECTIVE The aim of this study was to investigate the clinical characteristics of nocturia in patients with interstitial cystitis (IC), and the effects of bladder hydrodistention (with fulgurationContinue Reading
  • Hideaki Miyake, Yuto Matsushita, +4 authors Atsushi Otsuka
  • Medicine
  • International Journal of Clinical Oncology
  • 2017 (First Published: 1 June 2018)
  • BackgroundTo investigate whether the response to an androgen receptor-axis-targeted (ARAT) agent is associated with the efficacy of subsequent docetaxel in metastatic castration-resistant prostateContinue Reading